CA2414401A1 - Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic - Google Patents

Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic Download PDF

Info

Publication number
CA2414401A1
CA2414401A1 CA002414401A CA2414401A CA2414401A1 CA 2414401 A1 CA2414401 A1 CA 2414401A1 CA 002414401 A CA002414401 A CA 002414401A CA 2414401 A CA2414401 A CA 2414401A CA 2414401 A1 CA2414401 A1 CA 2414401A1
Authority
CA
Canada
Prior art keywords
cancer
drug
coupling
transferrin
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002414401A
Other languages
English (en)
Inventor
Ward Page Faulk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2414401A1 publication Critical patent/CA2414401A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne la diffusion ciblée de médicaments cytotoxiques : A) à des lymphocytes responsables du rejet de tissus transplantés, comme des reins, des coeurs ou des cellules de moelle osseuse. B) L'invention concerne l'utilisation d'un système non-toxique de diffusion existant naturellement afin de transporter de fortes concentrations de radiosensibiliseurs des cellules cancéreuses. C) L'invention concerne également la diffusion ciblée de médicaments en cas de diagnostic médical et de traitement du cancer.
CA002414401A 2000-06-28 2001-06-28 Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic Abandoned CA2414401A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21438800P 2000-06-28 2000-06-28
US21442700P 2000-06-28 2000-06-28
US21438900P 2000-06-28 2000-06-28
US60/214,389 2000-06-28
US60/214,427 2000-06-28
US60/214,388 2000-06-28
PCT/US2001/020444 WO2002000170A2 (fr) 2000-06-28 2001-06-28 Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic

Publications (1)

Publication Number Publication Date
CA2414401A1 true CA2414401A1 (fr) 2002-01-03

Family

ID=27395985

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002414401A Abandoned CA2414401A1 (fr) 2000-06-28 2001-06-28 Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic

Country Status (6)

Country Link
EP (1) EP1305051A4 (fr)
JP (1) JP2004501171A (fr)
AU (1) AU2001271525A1 (fr)
CA (1) CA2414401A1 (fr)
IL (1) IL153586A0 (fr)
WO (1) WO2002000170A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094271A1 (fr) 2001-05-15 2002-11-28 Faulk Pharmaceuticals, Inc. Administration ciblee de composes bioactifs pour le traitement du cancer
WO2002092116A1 (fr) 2001-05-15 2002-11-21 Faulk Pharmaceuticals, Inc. Administration ciblee de medicaments pour le traitement d'infections virales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US5108987A (en) * 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
GB8519457D0 (en) * 1985-08-02 1985-09-11 Faulk Ward Page Tumour imaging agents
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5792458A (en) * 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
CA2016584C (fr) * 1989-05-17 1999-06-29 Robert S. Greenfield Conjugats d'anthracycline ayant un nouvel adapteur et methodes de production
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals

Also Published As

Publication number Publication date
WO2002000170A2 (fr) 2002-01-03
WO2002000170A3 (fr) 2002-08-08
AU2001271525A1 (en) 2002-01-08
EP1305051A4 (fr) 2007-01-10
EP1305051A2 (fr) 2003-05-02
IL153586A0 (en) 2003-07-06
JP2004501171A (ja) 2004-01-15

Similar Documents

Publication Publication Date Title
US7001991B2 (en) Targeted delivery of bioaffecting compounds for the treatment of cancer
AU2005270336B2 (en) Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
Jansen et al. Immunotoxins in cancer therapy
Baron et al. Hematopoietic cell transplantation: five decades of progress
CA1222694A (fr) Immunochimiotherapie pour tumeurs malignes, particulierement pour le cancer du pancreas
US8183208B2 (en) Targeted delivery of drugs for the treatment of viral infections
US20090068104A1 (en) Substantially Homogeneous Bio-Affecting Material Having a Pre-Determined Ratio of Bioaffecting Component to Cell Targeting Component, the Method for Making Such a Material and the Method of its use
US5798097A (en) Immunogobulin conjugates
US20080095802A1 (en) Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer
CA2414401A1 (fr) Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic
EP0426924A1 (fr) Production de compositions avec la propriété de transporter des métaux pour faciliter la greffe de moelle osseuse histo-incompatible et pour contrôler les réactions immunes dans l'hôte
AU2007201744A1 (en) Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients with transplanted organs, B) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and C) in vitamin binding proteins as drug carriers in the diagnosis and treatment of cancer
Sedlacek et al. The change in research for the therapy of tumors
CZ214697A3 (en) Use of photosensitive preparation for preparing a medicament intended for restriction of aloimplant rejection
Dytfeld New opportunities in immunotherapy in multiple myeloma
Dullens et al. Oncostatic-antibody complexes in chemotherapy
US20040152071A1 (en) Targeted delivery of drugs for the treatment of viral infections
RU2009500C1 (ru) Способ получения цитотоксического коньюгата
Shields et al. Bone marrow toxicity of total-body irradiation combined with radiosensitizers
Thorpe et al. Monoclonal antibody therapy:“model” experiments with toxin-conjugated antibodies in mice and rats
AU2008202624B2 (en) Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use
WO1998056823A1 (fr) Induction d'immunotolerance par immunotoxine
Uhr et al. The Use of Ricin a Chain-Containing Immunotoxins to Kill Neoplastic B Cells
US20030228253A1 (en) Radiolabelled thioplatin, compositions thereof and methods of cancer treatment
Brendel et al. 11th Round Table Symposium on Applied Immunology, Axams/Tirol, January 28–30, 1980

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued